Lab and Office Renovation
United Therapeutics is pushing the limits of innovation, tackling the national shortage of transplantable organs with advanced biotechnology tools that either delay the need or expand the supply of these organs. To support this mission, they needed a state-of-the-art lab and research facility—one that attracts top talent and adapts to rapid advancements.
Transitioning from a co-working space in Kendall Square to a revitalized 19th-century mill building in nearby New Hampshire, Page designed a flexible, Good Lab Practice (GLP) compliant facility that seamlessly integrates future equipment and beta testing for emerging technologies. Built for evolution, the space ensures that groundbreaking research isn’t just supported—it thrives.
By blending history with innovation, this transformation empowers researchers to expand the possibilities of organ transplantation and lifesaving therapies.
For many patients with end-stage lung disease, a transplant is their only hope—but nearly 75% of donated lungs go unused. To address this crisis, United Therapeutics is pioneering 3D organ bioprinting, using human collagen fibers grown in genetically modified tobacco plants.
Page designed a flexible, high-performance lab and office space to support this innovation. Meeting Good Laboratory Practices (GLP) standards, the facility allows for future equipment and beta testing, ensuring adaptability as technology evolves.
A transparent layout co-locates labs and offices, promoting collaboration and allowing researchers to visualize the workflow—from cellular screening and 3D bioprinting to scanning and microscopy. Lab and support spaces align with the multiple stages of developing lab-grown lungs, streamlining research and production.
Located in a historic Amoskeag Mill building, the design balances state-of-the-art infrastructure with preservation constraints, maintaining an open, efficient workspace. Highly specialized MEP systems were engineered for adaptability, supporting evolving research needs.
By designing a facility that fosters innovation and accelerates discovery, Page and United Therapeutics are shaping the future of transplant medicine—bringing life-changing solutions closer to reality.
As part of Page’s two-phase expansion of lab and office space, the team envisioned an open, interconnected environment where scientists and support staff can move seamlessly between floors—enhancing collaboration in research, analytics, and production.
/
United Therapeutics is transforming the future for those living with pulmonary arterial hypertension (PAH) by developing breakthrough medications and leading cure research. A key focus of their work is increasing the availability of transplantable lungs through ex vivo lung perfusion (EVLP), a technology that reduces swelling in donor lungs, significantly improving their viability for transplant.
Similar projects
/
Talk with us
Complex challenges need fresh perspectives and deep expertise. Connect with our team to explore how we can help you create spaces that make a real difference.